Imperial College London

Dr Robin Carhart-Harris

Faculty of MedicineDepartment of Brain Sciences

Research Fellow



+44 (0)20 7594 7992r.carhart-harris




Miss Bruna Cunha +44 (0)20 7594 7992




Burlington DanesHammersmith Campus






BibTex format

author = {Carhart-Harris, RL and Bolstridge, M and Day, CMJ and Rucker, J and Watts, R and Erritzoe, DE and Kaelen, M and Giribaldi, B and Bloomfield, M and Pilling, S and Rickard, JA and Forbes, B and Feilding, A and Taylor, D and Curran, HV and Nutt, DJ},
doi = {10.1007/s00213-017-4771-x},
journal = {Psychopharmacology},
pages = {399--408},
title = {Psilocybin with psychological support for treatment-resistant depression: six-month follow-up},
url = {},
volume = {235},
year = {2017}

RIS format (EndNote, RefMan)

AB - RATIONALE: Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. OBJECTIVES: Here, we report on safety and efficacy outcomes for up to 6 months in an open-label trial of psilocybin for treatment-resistant depression. METHODS: Twenty patients (six females) with (mostly) severe, unipolar, treatment-resistant major depression received two oral doses of psilocybin (10 and 25 mg, 7 days apart) in a supportive setting. Depressive symptoms were assessed from 1 week to 6 months post-treatment, with the self-rated QIDS-SR16 as the primary outcome measure. RESULTS: Treatment was generally well tolerated. Relative to baseline, marked reductions in depressive symptoms were observed for the first 5 weeks post-treatment (Cohen's d = 2.2 at week 1 and 2.3 at week 5, both p < 0.001); nine and four patients met the criteria for response and remission at week 5. Results remained positive at 3 and 6 months (Cohen's d = 1.5 and 1.4, respectively, both p < 0.001). No patients sought conventional antidepressant treatment within 5 weeks of psilocybin. Reductions in depressive symptoms at 5 weeks were predicted by the quality of the acute psychedelic experience. CONCLUSIONS: Although limited conclusions can be drawn about treatment efficacy from open-label trials, tolerability was good, effect sizes large and symptom improvements appeared rapidly after just two psilocybin treatment sessions and remained significant 6 months post-treatment in a treatment-resistant cohort. Psilocybin represents a promising paradigm for unresponsive depression that warrants further research in double-blind randomised control trials.
AU - Carhart-Harris,RL
AU - Bolstridge,M
AU - Day,CMJ
AU - Rucker,J
AU - Watts,R
AU - Erritzoe,DE
AU - Kaelen,M
AU - Giribaldi,B
AU - Bloomfield,M
AU - Pilling,S
AU - Rickard,JA
AU - Forbes,B
AU - Feilding,A
AU - Taylor,D
AU - Curran,HV
AU - Nutt,DJ
DO - 10.1007/s00213-017-4771-x
EP - 408
PY - 2017///
SN - 0033-3158
SP - 399
TI - Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
T2 - Psychopharmacology
UR -
UR -
VL - 235
ER -